Generali Asset Management SPA SGR Acquires 7,574 Shares of Illumina, Inc. $ILMN

Generali Asset Management SPA SGR increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 51.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 22,249 shares of the life sciences company’s stock after purchasing an additional 7,574 shares during the period. Generali Asset Management SPA SGR’s holdings in Illumina were worth $2,113,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Parkside Financial Bank & Trust raised its stake in Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares in the last quarter. Rise Advisors LLC grew its holdings in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the last quarter. Cullen Frost Bankers Inc. bought a new stake in shares of Illumina during the 2nd quarter valued at approximately $41,000. NewSquare Capital LLC increased its position in Illumina by 604.9% during the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after purchasing an additional 369 shares in the last quarter. Finally, Mather Group LLC. bought a new position in Illumina in the 3rd quarter valued at approximately $46,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Trading Up 2.4%

NASDAQ ILMN opened at $134.35 on Friday. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $153.06. The business has a 50 day moving average price of $125.81 and a 200-day moving average price of $107.86. The company has a market cap of $20.53 billion, a price-to-earnings ratio of 30.12, a P/E/G ratio of 2.24 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.18. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. Illumina’s revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research reports. TD Cowen boosted their target price on shares of Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a research note on Friday, October 31st. Cowen reissued a “hold” rating on shares of Illumina in a report on Friday, October 31st. Barclays upped their target price on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Canaccord Genuity Group lifted their price target on Illumina from $112.00 to $130.00 and gave the company a “hold” rating in a research note on Monday, December 22nd. Finally, Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Five equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $118.31.

Insider Activity

In other news, insider Scott M. Davies sold 323 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Scott Gottlieb bought 500 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were bought at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the transaction, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 2.60% of the stock is currently owned by company insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.